Nolvadex (Tamoxifen Citrate)

Tamoxifen citrate, the active ingredient in Nolvadex, is a selective estrogen receptor modulator presented as an oral tablet for oral use. It is employed in the treatment and prevention of estrogen‑dependent breast conditions and in managing gynecomastia in appropriate patients.

GNH USA supplies Nolvadex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nolvadex (tamoxifen citrate) acts on estrogen‑dependent pathways and is used in several breast‑related conditions.

- Estrogen receptor‑positive breast cancer: reduces tumor growth and recurrence. - Adjuvant therapy for breast cancer: decreases risk of disease return after surgery. - High‑risk women for breast cancer: lowers incidence of developing the disease. - Gynecomastia: alleviates breast tissue enlargement in men.

Adverse reactions may occur with tamoxifen therapy and vary in frequency.

Common Side Effects: - Hot flashes: transient sensation of warmth. - Nausea or vomiting: mild to moderate gastrointestinal upset. - Menstrual irregularities: changes in cycle timing or flow. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Deep‑vein thrombosis or pulmonary embolism: signs of clot formation. - Endometrial cancer: abnormal uterine bleeding. - Severe liver injury: jaundice or elevated liver enzymes. - Visual disturbances: blurred vision or retinal changes.

Before initiating tamoxifen, clinicians should consider several safety aspects.

- Monitor liver function: assess baseline enzymes and periodic testing. - Assess thromboembolic risk: evaluate history of clotting disorders. - Avoid use in pregnancy: teratogenic potential requires effective contraception. - Consider bone health: monitor for osteoporosis in long‑term therapy. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Tamoxifen may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): reduce conversion to active metabolites. - Warfarin: may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower tamoxifen levels. - Antacids or supplements containing calcium/magnesium: could affect absorption. - Hormonal contraceptives: may reduce contraceptive effectiveness.